- Compass Pathways (NASDAQ:CMPS) is making significant progress with its COMP360 psilocybin therapy for treatment-resistant depression, supported by positive Phase 3 clinical trial results.
- Analyst firm Oppenheimer has reiterated an “Outperform” rating for Compass Pathways, citing strong data and improved launch prospects for its main therapy.
- The company’s long-term data reinforces a planned 2027 launch, with the stock showing recent positive movement and a market capitalization of approximately $1.24 billion.
Compass Pathways (NASDAQ:CMPS) is a mental health care company. It focuses on developing innovative therapies for difficult-to-treat mental health conditions. The company is known for its research into psilocybin therapy, particularly its proprietary synthetic psilocybin formulation, COMP360, for treatment-resistant depression (TRD).
On July 7, 2026, analyst firm Oppenheimer restated its “Outperform” rating for Compass Pathways when the stock was priced at $12.64. As highlighted by TheFly, Oppenheimer’s confidence comes from recent data that it believes improves the company’s future launch prospects for its main therapy.
This positive outlook is supported by 26-week results from Compass Pathways’ second Phase 3 trial, COMP006. The clinical trial, which studies COMP360 for TRD, confirms the treatment has a rapid and lasting effect. These findings are consistent with a previous Phase 3 trial, COMP005, which also showed a good safety profile.
The long-term data from the study, involving nearly 600 patients, reinforces Compass Pathways’ planned launch timeline for 2027. This suggests the company is on track to bring its synthetic psilocybin therapy to market.
Following the news, Compass Pathways is trading at $12.94, an increase of 0.74% for the day. The stock has a 52-week range between $3.34 and $15.40. The company currently has a market capitalization, or total market value, of approximately $1.24 billion, with a trading volume of about 10.54 million shares.
